

# **Patient Engagement and Patient Experience Data: Understanding Their Use in Medicines Regulation and Healthcare Decision Making and the Implications for Medical Affairs**

**Lumanity**

November 04, 2022

# Moderator and Panelists



**Michael Parisi**

**Moderator**

Global President of  
Communications

Lumaniy

United States



**Nicholas Brooke**

Executive Director

Patient Focused Medicines  
Development (PFMD)

Belgium



**Professor Lara Bloom**

President & CEO

The Ehlers-Danlos Society

United Kingdom



**Susan Stein**

Executive Director

Medical Affairs  
Patient Advocacy

TP Therapeutics/BMS

United States



# Conflict of Interest and Disclosures

MAPS is committed to ensuring full disclosure of potential Conflicts of Interest (COI) by session presenters/developers. While a presenter COI is not prohibited nor necessarily harmful to the learner, it is important that this be shared with the learner so the learner may make an informed decision regarding material presented. A COI includes any transaction or relationship which presents, or may present, a conflict between a presenter/developer's - or his/her spouse/life partner's - personal, business or other interests.

- The panelists do not have any conflicts of interest
- Please see the Credit Disclosure page for full details on faculty and planning member disclosures.

# Housekeeping

A warm welcome to all!



This session is being recorded. Please mute your microphone when not speaking



Please ensure mobile phones are turned off or on silent throughout the meeting



If you need any assistance during the meeting, please message or email:

**Mary Gluckle**  
**[mgluckle@medicalaffairs.org](mailto:mgluckle@medicalaffairs.org)**

# Learning Objectives

**Understand** the importance of the role of Medical Affairs in creating meaningful and effective patient engagement

**Share** current best practice related to the use of patient engagement and patient experience data

**Share** insight on what patients and their advocates need from their industry partners for better patient engagement

**Discuss** how Medical Affairs is well positioned to support patient engagement and use of patient experience data post-launch



# Agenda

## Topic 1

Setting the Scene

Michael Parisi and  
Nicholas Brooke

## Topic 2

Personal Perspectives:  
How is Medical Affairs Uniquely  
Placed to Explore Patient  
Engagement and Patient  
Experience Data

Whole panel  
discussion

## Topic 3

Live Audience  
Q&A

Whole panel  
discussion

## Topic 4

Concluding  
Remarks and  
Close

Michael Parisi

# Topic 1 – Setting the Scene

*Michael Parisi and Nicholas Brooke*

# Poll

Progress

# Q1

Are you **personally involved** in patient engagement as part of your role?

Yes

No




# Q2

Is there **alignment internally** on what patient experience data is used for and what it can help to inform?


Yes

No

# PE and PED: Acceleration Continues in the Last 6 Months



# A Framework to Build on Solutions for PE in Post-launch



# PE and PED Fusion: Meaningful PED Needs PE for Co-creation and Contextualization

Patient experience data does not “replace” patient engagement

Patient Experience Data

Patient Engagement

## Contextualize:

Ensure patient participation in decision-making processes

Provides context and understanding of the results

## Co-create/Create:

Ensures PED is focused on patient-meaningful topics

Co-design evidence generation to ensure it is meaningful

Patient experience data needs patient engagement throughout

# Both PE and PED Are Currently Used to Answer Patient-related Questions

## Patient Experience Data

### FDA Guidance on Patient Experience Data

Signs and symptoms and impact on everyday life

Changes in disease and its impact over time

Experience with treatments and disease management approaches

Expectations and views and desired treatment outcomes

Trade-offs between outcomes, benefits, and risks



## Patient Engagement

### Questions during HTA Patient Engagement

Signs and symptoms and impact on everyday life

Burden of disease

Experience with current treatments and disease management approaches

Expectations of the new treatment and its outcomes  
Perceptions of downsides of the new treatments

Potential impact (positive and negative) on family and caregivers

# We've Heard of Challenges with PE and PED from Many Stakeholders

## PATIENT ORGANIZATION



“Clinical outcome assessments and patient preferences do not collectively reflect all patient experience”



“We have the capacity to collect patient evidence, but **will it be considered?**”



“There is a **duplication of efforts**, with many parallel initiatives, and stakeholders that want similar things”

## SPONSORS



“How are **other companies** defining and including PED and PE in their submissions?”



“The point of submitting PED is speculative as we are **not clear how it is being used or evaluated**”

## REGULATORS




“We need to address the **disconnect between guidance and what is actually done** in practice”



“**Diverse perspectives and opinions make PED difficult to define** and a bigger picture is needed for collaboration”

# PE initiatives can amplify the Cone of Double Materiality



# Topic 2 – Personal Perspectives

*Whole Panel Discussion*



# Personal Perspectives

Progress

# Q1

Why is it important to not only collect patient experience data and insights, but to also **engage directly** with individuals with lived experiences?

Answers

# Personal Perspectives

Progress

# Q2

How do we **streamline patient engagement** and data collection in the industry?

Answers

# Personal Perspectives

Progress

# Q3

What are patient associations doing to **prepare for new regulation** in patient engagement, particularly in the post-launch period?

# Personal Perspectives

Progress

# Q4

What are the **common barriers** you experience when implementing patient engagement strategies, and how might Medical Affairs help to overcome these?

Answers

# Personal Perspectives

Progress

## Q5

What **resources or guidance** are available for Medical Affairs to better understand or address these barriers?

Answers

# Personal Perspectives

Progress

# Q6

What would be the **one thing** you would suggest to Medical Affairs colleagues to make a material difference in their organizations now?

Answers

# Topic 3 – Live Audience Q&A

*Whole panel discussion*

# Topic 4 – Concluding Remarks and Close

*Michael Parisi and Nicholas Brooke*



Q7

**What resources or guidance**  
are available for Medical Affairs  
to better understand the  
topics or address the barriers?

Answers

# Recommended tools to aid patient engagement implementation

- **Patient Engagement Management Suite**  
[PEMsuite.org](https://PEMsuite.org)
- **Global PED navigator** (via PEMsuite)
- **MAPS website** – Content Hub (search by Patient Centricity)  
[medicalaffairs.org/content-hub](https://medicalaffairs.org/content-hub)
- **National Health Council (NHC)** - Resources  
[nationalhealthcouncil.org/resources](https://nationalhealthcouncil.org/resources)



**BETA**

Global Patient Experience Data Navigator

The current matrix can help you identify the methods or tools for measuring outcomes that matter to patients & families. In grey you can see what methods are the most appropriate for a specific area of impact.

Qualitative methods	PROs	CTRs	Obs	PerCs	DRIs (Digital Health Technologies)
Qualitative methods	PROs	CTRs	Obs	PerCs	DRIs (Digital Health Technologies)

The Stakeholder matrix helps you understand how Patient Experience Data is used in the drug development process and the healthcare process. The matrix gives you the opportunity to see the collective value behind PED use. This view would support stakeholder alignment to avoid duplication and inefficiencies.

Stakeholder	Real World Data	Symptoms identification	Diagnosis	Treatment choices	Therapy cycles	Disease progression or surveillance
Stakeholder	Real World Data	Symptoms identification	Diagnosis	Treatment choices	Therapy cycles	Disease progression or surveillance

Stakeholder matrix helps you understand how Patient Experience Data is used in the drug development process and the healthcare process. The matrix gives you the opportunity to see the collective value behind PED use. This view would support stakeholder alignment to avoid duplication and inefficiencies.

**How-To Guides for Patient Engagement**

- How-to Guide for Patient Engagement in the Early Discovery and Preclinical phases
- How-to Guide on Patient Engagement in the development of a clinical outcome assessment (COA) strategy
- How-to Guide on Patient Engagement in clinical trial protocol design
- Plain language summaries (PLS) of peer-reviewed publications and conference presentations practical How-To Guide for multi-stakeholder co-creation
- Guidance for Community Advisory Boards
- Guidance for Patient Engagement in Early Diagnosis (HFA)

**Global Patient Experience Data Navigator**

- Recent Regulatory & HTA updates on PE & PED
- Other tools coming soon

**Pharmaceutical Industry**

- Medical Technology
- Legal and contractual tools

**Patient Engagement & Patient Experience Data Fusion Tools**

- Global Patient Experience Data Navigator
- Recent Regulatory & HTA updates on PE & PED
- Other tools coming soon

**Patient Engagement Book of Good Practices**

- Multiple editions
- Medicines Development Lifecycle
- Medical Technology

**Monitoring to Learn Tools**

- Patient Engagement Metric Selector
- Other tools coming soon

**Synopsis - The Patient Engagement Network**

- Map and Network
- Connecting communities on work related to medicines development & beyond: medicinal health, precision medicine, medical technology & more
- People
- Organisations
- Initiatives
- Resources
- Events
- Performance metrics
- Conditions
- Training

**Patient Engagement Training**

For anyone working in the pharmaceutical or medtech sector

- Patient Engagement Basics**  
A 15-minute introduction to patient engagement and how to get it right (Level 1)
- Patient Engagement Value**  
What is patient engagement and how to get it right (Level 1)
- Patient Engagement In Practice**  
Your first step to making it happen (Level 2)
- PE Training and Resources Repository**  
A selection of patient engagement training courses and educational materials

**MAPS** Medical Affairs Professional Society

Home About Career Resources **Content HUB** MAPS Community Events

Search... Find

**CLEAR**

**SEARCH BY TYPE**

- E-Learning Courses
- Elevate Magazine
- Innovate Articles
- MAPS News & Updates

**Patient Centricity**

**Placing the Patient at the Heart of Medical Affairs**

October 31, 2022

In this episode, experts discuss patient-centricity strategies and

**Confronting the Life Science Diversity Problem**

October 21, 2022

In this e-book, learn how medical affairs teams can use technology to address diversity issues in the drug development life cycle.

# Closing Poll

Progress

# Q1

Do you feel **more confident** to become personally involved in patient engagement as part of your role?

Yes

No

# Closing Poll

Progress

# Q2

Can you see a role for Medical Affairs in **driving patient engagement** and patient experience data in your organization?

Yes

No

**Thank you!**